Research and Markets (http://www.researchandmarkets.com/research/hq557n/global) has announced the addition of the "Global Next-Generation Antibody Therapeutics Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering.

The global next-generation antibody therapeutics market was worth $ 1,328.3 million in 2014, and it is expected to grow at a CAGR of 44% during 2015-2020.

Next-generation antibody therapeutics market is escalating with high growth rate due to growing prevalence of chronic diseases. Some of the major reasons leading to increase in number of chronic disease cases include unhealthy lifestyle, poor diet, and addictions, such as smoking, and others.

The next-generation antibody therapeutics industry has made huge growth in the recent years. The growing healthcare expenditure has increased the overall research and development investment by various organizations. This leads to the growth of global next-generation antibody therapeutics market. The Autoimmune/Inflammatory market is growing at an average annual growth rate of over 46.4%. The Fc Engineered Antibodies market on the other hand grew at a CAGR of 56.8% during 2015-2020.

The restraints associated with next-generation antibody therapeutics market include high cost, stringent regulatory requirements and time consuming approval process of drugs. A significant capital investment is required for the research and manufacturing of next-generation therapeutics.

Key Topics Covered:

Chapter 1. Research Scope & Methodology

Chapter 2. Executive Summary

Chapter 3. Market Outlook

Chapter 4. Next-Generation Antibody Therapeutics Drug Pipeline Analysis

Chapter 5. Global Market Size And Forecast (2014 - 2020)

Chapter 6. Next-Generation Antibody Therapeutics Market Breakdown By Therapeutic Area

Chapter 7. Next-Generation Antibody Therapeutics Market Breakdown By Technology

Chapter 8. Next-Generation Antibody Therapeutics Market Breakdown By Geography

Chapter 9. Competitive Positioning And Market Share Analysis

Chapter 10. Company Profiles

Companies Mentioned:

  • Amgen Inc.
  • AstraZeneca PLC.
  • Bayer AG
  • Biogen
  • Bristol-Myers Squibb Company
  • Dyax Corp.
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen Inc.
  • Kyowa Hakko Kirin Co. Ltd.
  • Pfizer Inc.
  • Seattle Genetics Inc.
  • Takeda Pharmaceuticals Company Limited
  • Xencor Inc.

For more information visit http://www.researchandmarkets.com/research/hq557n/global